Gimeracil Size:Solid 2 mg A drug-drug interaction study to

A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

Mdivi-1 is a selective cell-permeable inhibitor of mitochondrial division dynamin-related GTPase (DRP1) and mitochondrial division dynamin I (Dnm1)

and may be new candidate for glima treatment in the clinic

Brain Res Dev Brain Res

2C2HF3O2/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45

Gimeracil Size:Solid 2 mg A drug-drug interaction study toGimeracil is a pyridine derivative with antitumor activity. Gimeracil enhances the antitumor activity of fluoropyrimidines by competitively and reversibly inhibiting the enzyme dihydropyrimidine dehydrogenase causing decreased degradation of the fluoropyrimidines. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). Product information CAS Number: 103766 25 2 Molecular Weight: 145. 54 Formula: C5H4ClNO2